RxDoctor Payments Data

Johnny Perez-Sanchez, MD

Internal Medicine · San Juan, PRNPI 1245347111

Payments from drug & device makers

$2,686in general payments, 2019–2025

Across 40 payments — averaging $67.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$379
  • Boehringer Ingelheim$309
  • Johnson & Johnson$242
  • Merck$184
  • Boston Scientific$146
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$2,58796%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,686 in reported general payments places this provider in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,338
Medicare patients
24
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban52$50,595
FarxigaDapagliflozin Propanediol55$49,566
SynthroidLevothyroxine Sodium322$36,507
JardianceEmpagliflozin33$35,390
Jentadueto XrLinagliptin/Metformin Hcl43$34,029
JanumetSitagliptin Phos/Metformin Hcl32$29,920
EliquisApixaban29$23,662
Trijardy XrEmpaglifloz/Linaglip/Metformin19$22,524
TradjentaLinagliptin15$15,108
JentaduetoLinagliptin/Metformin Hcl21$14,188
Janumet XrSitagliptin Phos/Metformin Hcl16$13,995
Atorvastatin Calcium581$7,422
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$7,313
Pentoxifylline80$5,800
Diclofenac Potassium157$5,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto Xr, Trijardy Xr, Tradjenta, Jentadueto$309$121,239131 claims
Johnson & JohnsonXarelto$242$50,59552 claims
AstraZenecaFarxiga$1,385$49,56655 claims
MerckJanumet, Janumet Xr$184$43,91548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →